Test Price
2,800 AED✅ Home Collection Available
KCNJ2 Gene Short QT Syndrome Type 3 (SQT3) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
✅ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
🚑 Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
📞 Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
💰 Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The KCNJ2 gene NGS test identifies pathogenic variants associated with Short QT Syndrome Type 3, a rare inherited cardiac channelopathy that can lead to sudden cardiac arrest. This comprehensive NGS assay provides >99.9% analytical sensitivity for all coding exons and flanking splice sites, enabling accurate risk stratification and family screening.
| Feature | Our ISO-Certified Test | Conventional Alternative |
|---|---|---|
| Methodology | NGS (Next Generation Sequencing) with 100% KCNJ2 coding region coverage | Sanger sequencing (single exon, limited throughput) |
| Analytical Sensitivity | >99.9% for SNVs and indels | Variable, may miss large rearrangements |
| Turnaround Time | 3–4 Weeks (with expedited option) | 4–6 Weeks |
| Post-Test Support | Included telephonic clinical guidance and genetic counseling referral | Not standardized |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasize that this genetic test is a powerful tool but must be interpreted within the full clinical context, including ECG, family history, and symptoms. A negative result does not completely exclude other genetic or acquired causes of short QT, and positive findings should lead to comprehensive cardiac evaluation. Please discuss all results with your healthcare provider before any lifestyle or treatment changes.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Important Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. This genetic test provides risk information but does not replace ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Patients with acute myocardial infarction or hemodynamic instability.
- Inability to provide informed consent (minors require legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- ER Red Flags: Sudden syncope, severe chest pain, palpitations with dizziness – call 998 immediately.
Patient FAQ & Clinical Guidance
1. Who should consider genetic testing for Short QT Syndrome Type 3?
Individuals with a personal or family history of unexplained sudden cardiac arrest, abnormally short QT interval on ECG (≤330 ms), or known familial KCNJ2 mutation should consider this test.
2. How is the KCNJ2 genetic test performed?
A simple blood draw or dried blood spot sample is collected at home by a certified phlebotomist via our VIP Mobile Phlebotomy service and sent to our ISO-accredited lab for NGS analysis.
3. What do the results mean and what is the turnaround time?
Results are reported as pathogenic/likely pathogenic, variant of uncertain significance, or negative, with detailed interpretation; turnaround time is 3–4 weeks.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
This test complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory processing is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | KCNJ2 Gene Sequencing (Short QT Syndrome Type 3) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (or dried blood spot) collected via VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection |
| Methodology Used | Next Generation Sequencing (NGS) – Full coding region and splice site analysis |
| ICD-10-CM Code | I45.82 (Short QT syndrome) |
| LOINC Code | 92076-6 (KCNJ2 gene targeted mutation analysis in Blood or Tissue by NGS) |
| DHA Facility License & Lab Address | DHA Facility License Number: 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians